A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder
ID Number 14-0597Principal Investigator(s)
Department(s) or Division(s)
The purpose of this study is to test the safety tolerability and efficacy of ezogabine as a new antidepressant treatment for individuals suffering from major depressive disorder. Ezogabine is a potassium (K+) KCNQ2-selective channel potentiator and is believed to improve mood in individuals experiencing depression. Ezogabine is a take-home medication currently approved by the Food and Drug Administration (FDA) as an adjunctive treatment for partial-onset seizures but is still considered experimental for depression. One may qualify to take part in this research study if s/he has been diagnosed with major depressive disorder (MDD) and is currently experiencing depression. Participation in this study is expected to last about 12 weeks. Eligible participants will receive treatment at no cost and compensation for their time.
Recruiting Patients: Yes